Met my new oncologist yesterday

Posted by ncteacher @ncteacher, Jul 15, 2023

I've posted twice about my frustrations with my first oncologist. I asked for a referral to another MD, and yesterday (Fri 7/14) we met for the first time. I think--hope!--we've hit the jackpot. Turns out this MD did his internal medicine residency at Mayo, his hospice/palliative care fellowship at MD Anderson and his hem/onc fellowship at University of Michigan. He spent nearly an hour with us. Answered all our questions; brought up info we hadn't been given before; ordered tumor marker blood tests before every chemo round (I had been told every 3 months, but he said Mayo did them more frequently and that was his preference too); got in contact with my internist about my physical next week; and said he was already poking around for possible clinical trials for ATM mutation if the chemo stops working. Right now, we're making no changes in treatment since everything looks positive so far. We'll reassess after chemo round 8, so mid- to late August, which is also earlier than I'd been told by the other MD. His bedside manner is much more sensitive than my first MD (he said that MD is more focused on administration, whereas his focus is research and patient care). All in all, we're really pleased. So far, so good!

Interested in more discussions like this? Go to the Pancreatic Cancer Support Group.

Oh, great news!! I'm very, very happy for you!

REPLY

Congrats; that's the way it should be. Hope you're not having to fly or drive too far. MD Anderson has a Phase 1-2 trials specialist who's totally focused on trial drugs related to DNA damage repair in ATM/BRCA/PALB mutations.

They had three relevant trials open when I talked to them in January. The two we discussed seriously had travel requirements to Houston that I couldn't accommodate at the time, but they remain in my back pocket as soon as my current SoC regimen quits working.

Also, if you haven't been screened for the BASECAMP trial, you should inquire about that. It's applicable to several tumor types and mutation types, but if you meet all the right combinations of blood characteristics of an HLA typing test, you could then qualify for the follow-on EVEREST trial, using CAR-T cells combined with an agent that prevents them from attacking healthy cells.

REPLY
Please sign in or register to post a reply.